twit 25   linkedin 25

16 / Jan 15

Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration

ONCODESIGN, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds.
The collaboration is based on Oncodesign’s platform of small macrocycles, Nanocyclix®, and will also engage the advanced oncology pharmacology models at Oncodesign for cancer applications, Predict®, Chi-mice® and Pharmimage®. The collaboration will potentially include multiple therapeutic areas and involve phenotypic cell-based approaches.
The goal of the collaboration is to generate novel Nanocyclix® based compounds for targets of interest to Bristol-Myers Squibb. These small macrocycles are highly potent and selective and have favorable characteristics allowing knowledge driven optimization beyond what is typically possible with conventional molecular designs.

About NewCap

As a specialist in investor relations and strategic communication advice, NewCap advises and supports its clients regarding their sectoral, scientific, institutional and financial communication strategies.


contact 01Address :
21, place de la Madeleine - 75008 Paris

contact 02Phone :
+33 (0)1 44 71 94 94

contact 03Email :